Cover Image
市場調查報告書

HIV (人類免疫缺乏病毒):現在·未來市場參與企業

Human Immunodeficiency Virus (HIV) - Current and Future Players

出版商 GlobalData 商品編碼 370559
出版日期 內容資訊 英文 132 Pages
訂單完成後即時交付
價格
Back to Top
HIV (人類免疫缺乏病毒):現在·未來市場參與企業 Human Immunodeficiency Virus (HIV) - Current and Future Players
出版日期: 2015年09月09日 內容資訊: 英文 132 Pages
簡介

本報告提供全球HIV (人類免疫缺乏病毒)治療藥市場上之現有/新加入企業相關分析,提供您整體市場趨勢預測和促進·阻礙因素,現在·未來的競爭趨勢,主要企業簡介(企業概要,財務狀況,策略發展情形,SWOT分析)等資訊。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 近日出版的相關報告

第3章 市場預測

  • 全球市場
    • 市場預測
    • 促進·阻礙因素:全球市場課題

第4章 現在·未來市場參與企業

  • 概要
  • 企業策略的趨勢
  • 企業簡介
    • Gilead Sciences
    • ViiV Healthcare
    • AbbVie
    • Merck & Co.
    • Janssen
    • Bristol-Myers Squibb
    • 日本煙草產業
    • Avexa
    • TaiMed Biologics
    • Tobira Therapeutics

第5章 附錄

圖表一覽

目錄
Product Code: GDHC1053FPR

GlobalData has released its pharma report, "Human Immunodeficiency Virus (HIV) - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Human Immunodeficiency Virus (HIV) Market. The report identifies and analyses the key companies shaping and driving the global Human Immunodeficiency Virus (HIV) market. The report provides insight into the competitive Human Immunodeficiency Virus (HIV) landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Human Immunodeficiency Virus (HIV)
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Human Immunodeficiency Virus (HIV) sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Human Immunodeficiency Virus (HIV) market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Human Immunodeficiency Virus (HIV) market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Gilead Sciences
    • 4.3.2. ViiV Healthcare
    • 4.3.3. AbbVie
    • 4.3.4. Merck & Co.
    • 4.3.5. Janssen
    • 4.3.6. Bristol-Myers Squibb
    • 4.3.7. Japan Tobacco
    • 4.3.8. Avexa
    • 4.3.9. TaiMed Biologics
    • 4.3.10. Tobira Therapeutics

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Total Prevalent Cases of HIV
    • 5.4.2. 20-Year Diagnosed Prevalent Cases of HIV
    • 5.4.3. HIV Cases Treated with ART
    • 5.4.4. Drugs Included in Each Therapeutic Class
    • 5.4.5. Launch and Patent Expiry Dates
    • 5.4.6. General Pricing Assumptions
    • 5.4.7. Individual Drug Assumptions
    • 5.4.8. Generic Erosion
    • 5.4.9. Pricing of Pipeline Agents
  • 5.5. Primary Research - KOLs Interviewed for This Report
  • 5.6. Primary Research - Prescriber Survey
  • 5.7. About the Authors
    • 5.7.1. Analyst
    • 5.7.2. Epidemiologists
    • 5.7.3. Therapy Area Director
    • 5.7.4. Global Director of Therapy Analysis and Epidemiology
    • 5.7.5. Global Head of Healthcare
  • 5.8. About GlobalData
  • 5.9. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($m) for HIV Therapeutics, 2013-2023
  • Table 2: Global HIV Therapeutics Market - Drivers and Barriers, 2013-2023
  • Table 3: Key Companies in the HIV-1 Market in the 9MM, 2014
  • Table 4: Gilead Sciences' HIV Portfolio Assessment, 2014
  • Table 5: Gilead Sciences, SWOT Analysis in HIV, 2013-2023
  • Table 6: ViiV Healthcare's HIV Portfolio Assessment, 2014
  • Table 7: ViiV Healthcare, SWOT Analysis in HIV, 2013-2023
  • Table 8: AbbVie's HIV Portfolio Assessment, 2014
  • Table 9: AbbVie, SWOT Analysis in HIV, 2013-2023
  • Table 10: Merck & Co.'s HIV Portfolio Assessment, 2014
  • Table 11: Merck & Co., SWOT Analysis in HIV, 2013-2023
  • Table 12: Janssen's HIV Portfolio Assessment, 2014
  • Table 13: Janssen, SWOT Analysis in HIV, 2013-2023
  • Table 14: BMS' HIV Portfolio Assessment, 2014
  • Table 15: BMS, SWOT Analysis in HIV, 2013-2023
  • Table 16: Japan Tobacco's HIV Portfolio Assessment, 2014
  • Table 17: Japan Tobacco, SWOT Analysis in HIV, 2013-2023
  • Table 18: Avexa's HIV Portfolio Assessment, 2014
  • Table 19: Avexa, SWOT Analysis in HIV, 2013-2023
  • Table 20: TaiMed Biologics, HIV Portfolio Assessment, 2014
  • Table 21: TaiMed Biologics, SWOT Analysis in HIV, 2013-2023
  • Table 22: Tobira Therapeutics, HIV Portfolio Assessment, 2014
  • Table 23: Tobira Therapeutics, SWOT Analysis in HIV, 2013-2023
  • Table 24: Key Historical and Projected Launch Dates for HIV Therapeutics Across the 9MM
  • Table 25: Key Historical and Projected Patent Expiry Dates for HIV Therapeutics Across the 9MM
  • Table 26: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Global Sales for HIV Therapeutics by Country, 2013-2023
  • Figure 2: Global Sales for HIV Therapeutics by Drug Class, 2013-2023
  • Figure 3: Company Portfolio Gap Analysis in HIV, 2013-2023
Back to Top